Surmodics Q2 2024 Adj EPS $0.07 Beats $(0.32) Estimate, Sales $31.958M Beat $28.844M Estimate
Portfolio Pulse from Benzinga Newsdesk
Surmodics reported Q2 2024 adjusted EPS of $0.07, surpassing the $(0.32) estimate, with sales of $31.958M exceeding the $28.844M forecast. This represents a 17.50% increase in sales compared to the same period last year.
May 01, 2024 | 11:01 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Surmodics reported a significant beat on both EPS and sales estimates for Q2 2024, with a notable year-over-year sales growth.
Surmodics' earnings and sales beat are likely to positively impact investor sentiment and the stock price in the short term. The substantial beat on both the EPS and sales estimates, coupled with a significant year-over-year sales growth, indicates strong company performance and operational efficiency. This positive news could lead to increased investor confidence and demand for SRDX shares, potentially driving up the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100